The risk-adjusted vision beyond casemix (DRG) funding in Australia Kathryn M. AntiochMichael K. Walsh Original Papers Pages: 95 - 109
The risk-adjusted vision beyond casemix (DRG) funding in Australia Kathryn M. AntiochMichael K. Walsh Erratum Pages: 115 - 115
Genetic screening, health care and the insurance industry Diego F. OssaAdrian Towse Original papers Pages: 116 - 121
Price-cost margin in the pharmaceutical industry Ismo LinnosmaaRaine HermansTaru Hallinen Original Papers Pages: 122 - 128
Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease Thomas HoffmannHelmut Brunner Original Papers Pages: 129 - 135
Potential cost-effectiveness of a family-based program in mild Alzheimer’s disease patients Janne MartikainenHannu ValtonenTuula Pirttilä Original Papers Pages: 136 - 142
Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine Francis FagnaniCamille Le FurMichel Gibergy Original Papers Pages: 143 - 149
An empirical analysis of the demand for physician services across the European Union Sergi Jiménez-MartínJosé M. LabeagaMaite Martínez-Granado Pages: 150 - 165
Economic growth, longevity and the epidemiological transition Olivier F. Morand Original papers Pages: 166 - 174
Dynamic competition in pharmaceuticals Laura MagazziniFabio PammolliMassimo Riccaboni Invited Papers Pages: 175 - 182
The European Network of Health Economic Evaluation Databases (EURO NHEED) Project John NixonPhilippe UlmannGérard de Pouvourville Scientific Information Pages: 183 - 187
“Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK” Nick BansbackSue WardJon Karnon Commentary Pages: 188 - 189
Pricing and reimbursement of drugs in Ireland Michael BarryLesley TilsonMáirín Ryan Pricing and Reimbursement Systems Pages: 190 - 194